Navigation Links
Quark Pharmaceuticals Presented At ARVO Data Showing That PF-04523655 Enters Retinal Cells And Elicits Its Pharmacologic Effect Via Target Gene Knock-Down Without Activating TLR3
Date:5/11/2009

es from Silence Therapeutics and from Alnylam Pharmaceuticals.

QPI-1007, a siRNA that utilizes a proprietary structure developed by Quark, is being evaluated in advanced IND-enabling preclinical studies as a neuroprotective agent for eye diseases. In addition, Quark has a broad pipeline of siRNA drug candidates based on novel structures developed internally. The Company expects to utilize the structures to develop additional RNAi drug candidates.

Quark is headquartered in Fremont, California and operates research and development facilities in Boulder, Colorado and Ness-Ziona, Israel. Additional information is available at www.quarkpharma.com.

    Quark Pharmaceuticals, Inc.        The Ruth Group (investors / media)
    Juliana Friedmann                  Sara Ephraim / Janine McCargo
    +972 89 30 5111                    (646) 536-7004 / 7033
    jfriedman@quarkpharma.com          sephraim@theruthgroup.com
                                       jmccargo@theruthgroup.com


'/>"/>
SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Quark Pharmaceuticals to Participate in 9th Annual Beyond Genome Conference
2. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
3. Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008
4. Quark Pharmaceuticals to Present at American Society for Pharmacology and Experimental Therapeutics Annual Meeting
5. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
11. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... the device," Nobel laureate Herbert Kroemer famously observed, ... at the junctures where layers of different materials ... interfaces between layers of metal oxides are becoming ... as spintronics, high-temperature superconductors, ferroelectrics and multiferroics. Realizing ...
(Date:1/15/2014)... 2014 The Pittcon Organizing Committee is pleased ... Safety Tech , an e-Journal and producer of ... the second year for the co-location of Food Labs Conference ... provides that the registration fee to attend the two-day Food ...
(Date:1/15/2014)... 2014 Look inside the new Preferred ... the lab, from fluid handling to instruments to supplies. ... when you order. , Preferred Solutions features a ... the L/S® model for precise flow control and dispensing ...
(Date:1/15/2014)... and SAN JOSE, California , January 15, ... developing antibody-drug conjugates for cancer, today announced the appointment of ... Dr Reynolds has over 20 years, development experience gained in ... Seattle Genetics. "I am delighted to welcome Tom ...
Breaking Biology Technology:A deeper look at interfaces 2Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3
... speciality,pharmaceutical company focused on the discovery and development ... problem of microbial,resistance, announces today the appointment of ... (SAB). Novexel,s SAB is chaired by Dr.,David Shlaes ... who is currently,Adjunct Professor at the Department of ...
... /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc.,(NYSE: ... company serving the,pharmaceutical, biotechnology, and medical device industries, ... announced its financial results for,fourth-quarter and full-year 2008. ... ), Highlights, ...
... March 25 David Koos, Chairman and CEO of ... BMSN), told the editors of The Wall Street Transcript, ... is an excellent possibility that the company "would have ... alliances and contracts "with companies engaged either in cryogenic ...
Cached Biology Technology:Novexel Strengthens its Scientific Advisory Board With the Appointment of Dr. Karen Bush 2Novexel Strengthens its Scientific Advisory Board With the Appointment of Dr. Karen Bush 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 2WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 4WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 6WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 7WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 8WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 9WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 10WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 11WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 12WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 13WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 14WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 15WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 16WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 17WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 18WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 19WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 20Bio-Matrix Scientific Group CEO Tells Wall Street Transcript That 'Positive Cash Flow' Is Possible in '09; New Stem Cell Banking Facility Is Growth Vehicle Over the Next Two Years, Says CEO in Exclusive News Interview 2
(Date:4/17/2014)... RSV infection , Respiratory syncytial virus (RSV) ... infections, generating life-threating illness in very young and ... limited. RSV enters host cells through the fusion ... bundle. Small interfering peptides that prevent bundle formation ... are highly susceptible to degradation. In this issue ...
(Date:4/17/2014)... NJ. April 16, 2014. Kessler Foundation has been ... million from the Department of Defense Spinal Cord ... principal investigator for the randomized, double-blinded, controlled, multi-site ... bone and muscle strength after spinal cord injury. ... & Engineering Research at Kessler Foundation. Two additional ...
(Date:4/17/2014)... cartridge developed at Sandia National Laboratories and recently licensed ... and cheaper. , Bacillus anthracis , the ... all over the world and can cause serious, and ... bacteria can survive in harsh conditions for decades. In ... through skin contact, inhalation of spores or eating contaminated ...
Breaking Biology News(10 mins):JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3
... apparent paradox exists: Despite choosing a career working with ... from mild disgust to extreme arachnophobia. ... Entomologist features the results of a survey involving ... fear of spiders. Although most entomologists had low scores ...
... producing the building blocks of life, amino acids, in research ... The team from Imperial College London, the University of ... icy comets collide into a planet, amino acids can be ... rocky meteorite crashes into a planet with an icy surface. ...
... has a simple message for fellow hypertension researchers: think ... percent of adults have high blood pressure and 50-75 ... powerful endothelin system, which helps the body eliminate salt, ... research and clinical world focus on suppressing a better-known ...
Cached Biology News:Arachnophobic entomologists: When 2 more legs make a big difference 2Scientists discover cosmic factory for making building blocks of life 2Hypertension researcher encourages colleagues to expand their focus 2Hypertension researcher encourages colleagues to expand their focus 3
For cleavage of 6xHis tags from proteins containing a Factor Xa Protease recognition site Efficient 6xHis tag cleavage (greater than 90%), ...
... PBL's bioassays for interferons are cytopathic effect inhibition ... Sample types include; tissue culture supernatents; serum ... these assays, one unit is defined as the ... the cytopathic effect of viral infection by 50%. ...
... The BioPrime Plus Array CGH Genomic Labeling ... enable reproducible labeling of genomic DNA samples ... in both indirect and direct labeling formats, ... Systems provide a flexible solution to your ...
... effect inhibition assays, also known as CPE and ... supernatents; serum from PK studies and delivery formulations. ... as the quantity of interferon required per milliliter ... by 50%. All standards used in ...
Biology Products: